Castration-Refractory Prostate Cancer: New Drugs in the Pipeline

被引：13
作者：
Schrijvers, Dirk [1 ]
Van Erps, Peter [2 ]
Cortvriend, Jim [2 ]
机构：
[1] Ziekenhuisnetwerk Antwerpen Middelheim, Dept Hematooncol, B-2020 Antwerp, Belgium
[2] Ziekenhuisnetwerk Antwerpen Middelheim, Dept Urol, B-2020 Antwerp, Belgium
来源：
ADVANCES IN THERAPY | 2010年 / 27卷 / 05期
关键词：
castration-refractory prostate cancer; docetaxel; cabazitaxel; abiraterone acetate; angiogenesis modulators; vaccines; PHASE-II TRIAL; ABIRATERONE ACETATE; 2ND-LINE CHEMOTHERAPY; PLUS PREDNISONE; CLINICAL-TRIAL; DOCETAXEL; INHIBITOR; CYP17; MITOXANTRONE; THALIDOMIDE;
D O I：
10.1007/s12325-010-0038-1
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naive or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.
引用
收藏
页码：285 / 296
页数：12
相关论文
共 50 条
  • [31] Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel
    Gallardo, Enrique
    Angel Arranz, Jose
    Pablo Maroto, Jose
    Angel Leon, Luis
    Bellmunt, Joaquim
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 88 (02) : 357 - 367
  • [32] Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis
    Ayer Botrel, Tobias Engel
    Clark, Otavio
    Lima Pompeo, Antonio Carlos
    Horta Bretas, Francisco Flavio
    Sadi, Marcus Vinicius
    Ferreira, Ubirajara
    dos Reis, Rodolfo Borges
    INTERNATIONAL BRAZ J UROL, 2012, 38 (06): : 717 - 727
  • [33] Corticotherapy in castration-resistant prostate cancer
    Lebdai, S.
    Branchereau, J.
    Robert, G.
    De La Tallie, A.
    Bouchaert, P.
    PROGRES EN UROLOGIE, 2013, 23 : S23 - S33
  • [34] Castration-Resistant Prostate Cancer Current and Emerging Treatment Strategies
    Di Lorenzo, Giuseppe
    Buonerba, Carlo
    Autorino, Riccardo
    De Placido, Sabino
    Sternberg, Cora N.
    DRUGS, 2010, 70 (08) : 983 - 1000
  • [35] Novel therapeutic approaches for the treatment of castration-resistant prostate cancer
    Heidegger, Isabel
    Massoner, Petra
    Eder, Iris E.
    Pircher, Andreas
    Pichler, Renate
    Aigner, Friedrich
    Bektic, Jasmin
    Horninger, Wolfgang
    Klocker, Helmut
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2013, 138 : 248 - 256
  • [36] Castration-Resistant Prostate Cancer-Hormone Therapy Redux
    Tolcher, Anthony W.
    Cooper, Josh
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1447 - 1449
  • [37] Castration Refractory Prostate Cancer: Cinderella Finally Comes to the Ball
    Chowdhury, Simon
    Harper, Peter
    Powles, Thomas
    ONKOLOGIE, 2010, 33 (12): : 655 - 656
  • [38] Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors
    Procopio, Giuseppe
    Grassi, Paolo
    Testa, Isabella
    Verzoni, Elena
    Torri, Valter
    Salvioni, Roberto
    Valdagni, Riccardo
    de Braud, Filippo
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (05): : 479 - 482
  • [39] Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer
    Fitzpatrick, John M.
    de Wit, Ronald
    EUROPEAN UROLOGY, 2014, 65 (06) : 1198 - 1204
  • [40] Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting?
    Dulgar, Ozgecan
    ozyukseler, Deniz Tataroglu
    Basak, Mustafa
    Ay, Seval
    Tural, Deniz
    Yildirim, Mahmut Emre
    Gumus, Mahmut
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (06) : 1388 - 1394
12345